NV-WESTFALL-TECHNIK
2.7.2021 20:24:05 CEST | Business Wire | Press release
Westfall Technik, Inc. (“Westfall”, the “Company”), a global holding company that provides superior manufacturing solutions for the production of plastic parts in the medical, packaging, and consumer goods industries, announced today the acquisition of Carolina Precision Plastics, LLC (d/b/a “CPP Global” or “CPP”) and its wholly owned subsidiaries.
The deal greatly strengthens Westfall’s geographic footprint by adding its first plants in the southeastern United States, specifically in Mocksville and Asheboro, NC, as well in Kaiping, China, in Guangdong Province. “This provides a further supply-chain advantage to Westfall when it comes to serving key customers in both the packaging and healthcare sectors,” said Merritt Williams, the firm’s Chief Commercial Officer. “CPP’s North Carolina plants are ideally located to serve the multitude of brand owners with a manufacturing presence in the surrounding area.”
CPP, which runs about 100 injection molding machines in its three facilities, also brings expertise in vital secondary services, such as high-volume, fully automated assembly and sophisticated decorating capabilities. In total, CPP’s three plants cover some 335,000 square feet of manufacturing space.
“This is just the next step in creating a truly world-class molding and tooling business that is built on a strong culture and unquestionable customer service,” according to Westfall CEO and founder Brian Jones.
A leader in North America in the injection molding of heavy-wall PET jars, CPP also operates an innovative, collaborative design center and has a strong sustainability profile. The firm is a significant user of recycled resins and biopolymers in its products.
“This highly strategic, synergistic deal greatly strengthens our presence in the fast-moving consumer goods segment,” said Mark Gomulka, Westfall’s Chief Operating Officer. “CPP Global is a valued packaging supplier to several leading personal care and beauty companies, such as L’Oréal (serving their L’Oréal Paris and Kiehl’s brands), Estée Lauder, and Burt’s Bees, among others.”
For CPP Chief Executive Officer Brian Tauber, the partnership with Westfall offers a clear path forward for continuing the upward growth trend that CPP Global is experiencing right now. “I’m thrilled to combine our strengths with the breadth and depth of Westfall’s capabilities to enhance our ability to provide our employees, customers, and other stakeholders with more opportunities to grow together,” said Tauber.
The terms of the investment were not disclosed. Westfall was represented by Morrison Cohen LLP as legal counsel. CPP Global was represented by Sheppard, Mullin, Richter & Hampton LLP as legal counsel and Stifel as financial advisor.
About Carolina Precision Plastics, LLC
Carolina Precision Plastics is a global plastic injection molder in the beauty care, cosmetics, beverage and consumer goods markets, providing its customers molding, assembly and decorating capabilities built on a foundation of an industry-leading lean culture. Its global manufacturing presence and commitment to a more sustainable packaging future afford customers the most efficient and environmentally responsible options for their packaging needs. Central to its Lean North Stars, CPP’s journey focuses on providing value to its customers and ensuring a safe, satisfying work environment to its entire team. For more, visit www.cppglobal.com .
About Westfall Technik, Inc.
Westfall Technik is a global holding company that provides highly productive plastics manufacturing solutions to the medical, consumer packaging and consumer goods industries. Since its founding in Las Vegas in October 2017, the company has acquired or launched at least 19 businesses across North America. Westfall Technik’s competitive advantages include modern automated systems, correlative molding processes, and effective industry 4.0 concepts. Brand owners can expect high quality products at an excellent value, a fast response for decreased time-to-market, 100% inspection and traceability from pellet to pallet, supply-chain security compliance, and reliability from a trustworthy team. For more, visit www.westfall-technik.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210702005408/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
